We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BI, Lilly Diabetes Drug Rejected By FDA, Recommended By EMA Panel
BI, Lilly Diabetes Drug Rejected By FDA, Recommended By EMA Panel
An EU panel of drug reviewers Friday urged approval of Boehringer Ingelheim and Eli Lilly’s diabetes drug empagliflozin, lauding the candidate just two weeks after the FDA turned it down.